tiprankstipranks
Oxford BioMedica plc (GB:OXB)
LSE:OXB
UK Market

Oxford BioMedica (OXB) Share Forecast & Price Target

Compare
56 Followers
See the Price Targets and Ratings of:

OXB Analyst Ratings

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Oxford
BioMedica
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OXB Stock 12 Month Forecast

Average Price Target

499.96p
▲(84.49% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Oxford BioMedica in the last 3 months. The average price target is 499.96p with a high forecast of 500.00p and a low forecast of 500.00p. The average price target represents a 84.49% change from the last price of 271.00p.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"167":"167p","500":"500p","250.25":"250.3p","333.5":"333.5p","416.75":"416.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":499.99999838782,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">500.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":499.96488635,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">499.96p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":499.99999838782,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">500.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[167,250.25,333.5,416.75,500],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Apr<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.5,431.23076910675536,436.9615382135108,442.69230732026614,448.42307642702156,454.1538455337769,459.88461464053233,465.6153837472877,471.3461528540431,477.0769219607985,482.8076910675539,488.53846017430925,494.26922928106467,{"y":499.99999838782,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.5,431.22806818076924,436.9561363615385,442.68420454230767,448.4122727230769,454.14034090384615,459.8684090846154,465.5964772653846,471.3245454461538,477.05261362692306,482.7806818076923,488.5087499884615,494.23681816923073,{"y":499.96488635,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.5,431.23076910675536,436.9615382135108,442.69230732026614,448.42307642702156,454.1538455337769,459.88461464053233,465.6153837472877,471.3461528540431,477.0769219607985,482.8076910675539,488.53846017430925,494.26922928106467,{"y":499.99999838782,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":213,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.5,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":287,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":381.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":405,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target500.00pAverage Price Target499.96pLowest Price Target500.00p
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan
450p490p
Hold
80.81%
Upside
Reiterated
12/03/24
Oxford Biomedica (OXB:LN) (OXBDF) PT Raised to GBP4.90 at JPMorganJPMorgan analyst James Gordon raised the price target on Oxford Biomedica (OXB:LN) (OTC: OXBDF) to GBP4.90 (from GBP4.50) while maintaining a Neutral rating.
RBC Capital
740p
Buy
173.06%
Upside
Reiterated
11/29/24
Deutsche Bank
250p380p
Hold
40.22%
Upside
Reiterated
09/24/24
Oxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche BankOxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche Bank
Investec
366p
Buy
35.06%
Upside
Upgraded
05/08/24
Oxford Biomedica upgraded to Buy from Hold at InvestecOxford Biomedica upgraded to Buy from Hold at Investec
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan
450p490p
Hold
80.81%
Upside
Reiterated
12/03/24
Oxford Biomedica (OXB:LN) (OXBDF) PT Raised to GBP4.90 at JPMorganJPMorgan analyst James Gordon raised the price target on Oxford Biomedica (OXB:LN) (OTC: OXBDF) to GBP4.90 (from GBP4.50) while maintaining a Neutral rating.
RBC Capital
740p
Buy
173.06%
Upside
Reiterated
11/29/24
Deutsche Bank
250p380p
Hold
40.22%
Upside
Reiterated
09/24/24
Oxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche BankOxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche Bank
Investec
366p
Buy
35.06%
Upside
Upgraded
05/08/24
Oxford Biomedica upgraded to Buy from Hold at InvestecOxford Biomedica upgraded to Buy from Hold at Investec
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

OXB Analyst Recommendation Trends

Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
4
5
3
3
1
Buy
1
0
0
1
1
Hold
2
3
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
8
5
6
4
In the current month, OXB has received 2 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. OXB average Analyst price target in the past 3 months is 499.96p.
Each month's total comprises the sum of three months' worth of ratings.

OXB Financial Forecast

OXB Earnings Forecast

Next quarter’s earnings estimate for OXB is -0.08p with a range of -0.08p to -0.08p. The previous quarter’s EPS was -0.31p. OXB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.37% of the time in the same period. In the last calendar year OXB has Preformed in-line its overall industry.
Next quarter’s earnings estimate for OXB is -0.08p with a range of -0.08p to -0.08p. The previous quarter’s EPS was -0.31p. OXB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.37% of the time in the same period. In the last calendar year OXB has Preformed in-line its overall industry.

OXB Sales Forecast

Next quarter’s sales forecast for OXB is 77.20M with a range of 77.20M to 77.20M. The previous quarter’s sales results were 50.81M. OXB beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.95% of the time in the same period. In the last calendar year OXB has Outperformed its overall industry.
Next quarter’s sales forecast for OXB is 77.20M with a range of 77.20M to 77.20M. The previous quarter’s sales results were 50.81M. OXB beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.95% of the time in the same period. In the last calendar year OXB has Outperformed its overall industry.

OXB Stock Forecast FAQ

What is GB:OXB’s average 12-month price target, according to analysts?
Based on analyst ratings, Oxford BioMedica plc’s 12-month average price target is 499.96p.
    What is GB:OXB’s upside potential, based on the analysts’ average price target?
    Oxford BioMedica plc has 84.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Oxford BioMedica plc a Buy, Sell or Hold?
          Oxford BioMedica plc has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Oxford BioMedica plc’s share price target?
            The average share price target for Oxford BioMedica plc is 499.96p. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 500.00p ,and the lowest forecast is 500.00p. The average share price target represents 84.49% Increase from the current price of 271p.
              What do analysts say about Oxford BioMedica plc?
              Oxford BioMedica plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Oxford BioMedica plc?
                To buy shares of GB:OXB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis